This author has yet to write their bio.Meanwhile lets just say that we are proud Haley Chartres contributed a whooping 133 entries.
Botanix Pharmaceuticals (ASX:BOT) is today hosting its Annual General Meeting (AGM) at 9:00am AWST at the offices of BDO, 38 Station Street, Subiaco, WA. To coincide with this event, the Company has shared an updated corporate presentation, which consolidates its progress in the past financial year and the valuable opportunities Botanix is pursuing in dermatology […]
Botanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company’s September quarterly update. Click here to view the report.
Botanix President and Executive Chairman, Vince Ippolito, was interviewed by Christine Corrado from Proactive’s New York studio yesterday. Their conversation focused on the recent launch of our BTX 1204A canine study for atopic dermatitis and our BTX 1702 rosacea study in Australia and New Zealand. In commenting on the potential for the atopic dermatitis study, […]
Botanix (ASX:BOT) is pleased to share a Quick Comment research report from leading stockbroking firm, Euroz Hartleys, following the Company’s release of a clinical development update on the atopic dermatitis and rosacea programs. Click here to view the report.
Botanix Pharmaceuticals (ASX:BOT) has today provided an update on its dermatology program, focusing on the BTX 1204A canine study for atopic dermatitis and BTX 1702 rosacea study. The BTX 1204A canine study for atopic dermatitis has now been launched. This will enrol 45 canines and evaluate two formulations of BTX 1204A. Positive data from a […]
Botanix (ASX:BOT) has expanded its management team with the appointment of new Senior Vice President of Pharmaceutical Development, Dr Jack Hoblitzell. Dr Hoblitzell brings over 30 years of extensive experience in leading world-class technical operations, manufacturing and supply chain management. He has held senior leadership roles in the US with companies including Pfizer, King Pharmaceuticals, […]
Botanix (ASX:BOT) is pleased to advise that leading adviser Euroz Hartleys has initiated coverage on Botanix as we lead into an exciting 12 months of clinical studies and corporate activities. This report reinforces our belief that Botanix has assembled the right people, technology and research strategies to advance our assets, and to deliver positive results […]
Botanix (ASX:BOT) is pleased to share leading stockbroking firm, Euroz Hartleys has initiated coverage of Botanix, with the release of a comprehensive 56-page initial report. Click here to view the report.
Botanix (ASX:BOT) has today published its Quarterly Activities Report and 4C Quarterly Cash Flow Report, for the period ended 30 June 2021. Key highlights from this period include: Successful launch of the BTX 1702 rosacea clinical study, currently under COVID related restrictions, with sites initiated in Australia and New Zealand start up pending Encouraging results […]
Skin specialists have reported an increase in people seeking treatment for skin conditions as a result of mandatory mask wearing in Australia due to COVID-19. Dubbed ‘maskne’, the condition includes acne, rosacea flare ups, perioral dermatitis, and folliculitis, all of which are aggravated by substances such as oil, bacteria, and dead skin cells becoming trapped […]